After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Most recently, Yahoo Finance reported about the stock as it publicized that MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
MNMD belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $5.56 and fluctuated between $5.66 as its day high and $5.02 as its day low. The current market capitalization of Mind Medicine Inc is $156.57M. A total of 1.4 million shares were traded on the day, compared to an average of 698.09K shares.
Insider Activity
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, MNMD has seen 0 BUY and 3 SELL insider trades, representing the acquisition of 0 and the disposition of 25,663 shares. Over the last 12 months, there were 17 BUYs and 25 SELLs from insiders. Insiders purchased 1,501,202 shares during that period but sold 560,466.
In the most recent transaction, Barrow Robert sold 13,237 shares of MNMD for 3.63 per share on Dec 26. After the transaction, the Chief Executive Officer now owns 596,721 company shares. In a previous transaction on Dec 26, Karlin Dan sold 6,774 shares at 3.63 per share. MNMD shares that Chief Medical Officer owns now total 365,030.
Among the insiders who sold shares, Greenway Schond L. disposed of 5,652 shares on Dec 26 at a per-share price of $3.63. This resulted in the Chief Financial Officer holding 216,617 shares of MNMD after the transaction. In another insider transaction, Barrow Robert sold 13,499 shares at $3.58 per share on Sep 25. Company shares held by the Chief Executive Officer now total 611,729.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for MNMD in the last 3 months, the mean price target is $26.00 with high estimates of $75.00 and low estimates of $8.00. In terms of 52-week highs and lows, MNMD has a high of $5.35 and a low of $2.41.
As of this writing, MNMD has an earnings estimate of -$0.46 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of -$0.29 per share and a lower estimate of -$0.57. The company reported an EPS of -$0.76 in the last quarter, which was -40.70% lower than expectations of -$0.54.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. MNMD’s latest balance sheet shows that the firm has $133.54M in Cash & Short Term Investments as of fiscal 2021. There were $0.00 in debt and $10.41M in liabilities at the time. Its Book Value Per Share was $2.39, while its Total Shareholder’s Equity was $151.66M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MNMD is Buy with a score of 4.86.
